Skip to main content
. 2017 Aug 11;8(46):80560–80567. doi: 10.18632/oncotarget.20156

Figure 4. Receiver operating characteristic (ROC) curve was performed to evaluate the threshold value of MMP-2 and TIMP-2 in differentiating lung cancer from benign diseases.

Figure 4

(A) The levels of MMP-2 were robust in discriminating patients with lung cancer form benign diseases with an area under the curves (AUC) value of 0.7536 (95% CI, 0.6512–0.8561). (B–D) Comparing lung cancer patients with benign group, the AUC for SCC, ADC, and SCLC were 0.7458 (95% CI, 0.6097–0.8820), 0.7708 (95% CI, 0.6513–0.8904), and 0.7396 (95% CI, 0.5937–0.8854), respectively. (E) The area under the ROC for TIMP-2 was 0.6219 (95% CI, 0.5049–0.7388). (F) In subgroup patients with SCLC, TIMP-2 have an AUC of 0.6229 (95% CI, 0.4224–0.8234).